(Q36954416)

17 August 2017

1 reference

title

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site (English)

1 reference

17 August 2017

0 references

1 reference

ChEBI release 2020-05-28

Seong S Shim

1

1 reference

17 August 2017

Michael D Hammonds

series ordinal

2

1 reference

17 August 2017

Baik S Kee

series ordinal

3

1 reference

17 August 2017

language of work or name

1 reference

27 September 2007

1 reference

European Archives of Psychiatry and Clinical Neuroscience

17 August 2017

published in

1 reference

17 August 2017

volume

258

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

16-27

1 reference

Dopamine in schizophrenia: a review and reconceptualization

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Functional and anatomical aspects of prefrontal pathology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Subtype progression and pathophysiologic deterioration in early schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0757-8

Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats.

21 January 2018

1 reference

12 December 2020

New antipsychotics and schizophrenia: a review on efficacy and side effects

1 reference

12 December 2020

D-serine added to clozapine for the treatment of schizophrenia

1 reference

12 December 2020

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

12 December 2020

Psychobiologic correlates of treatment response in schizophrenia

1 reference

12 December 2020

An NMDA Intervention Strategy in Schizophrenia With “Low-Dose” Milacemide

1 reference

12 December 2020

Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial

1 reference

12 December 2020

Oxidative stress, glutamate, and neurodegenerative disorders

1 reference

12 December 2020

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

1 reference

12 December 2020

NMDA Antagonist Neurotoxicity: Mechanism and Prevention

1 reference

12 December 2020

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

1 reference

12 December 2020

The two-syndrome concept and neuroendocrinology of schizophrenia.

1 reference

12 December 2020

Positron emission tomography studies of potential mechanisms underlying phencyclidine-induced alterations in striatal dopamine

1 reference

12 December 2020

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

1 reference

12 December 2020

Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones

1 reference

12 December 2020

The glycine site of the NMDA receptor--five years on.

1 reference

12 December 2020

An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics.

1 reference

12 December 2020

Treatment of schizophrenia negative symptoms: future prospects

1 reference

12 December 2020

Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients

1 reference

12 December 2020

Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex

1 reference

12 December 2020

Sarcosine based indandione hGlyT1 inhibitors

1 reference

12 December 2020

Effects of D-cycloserine on negative symptoms in schizophrenia

1 reference

12 December 2020

Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application.

1 reference

12 December 2020

The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias

1 reference

12 December 2020

Modulation of N-methyl-D-aspartate receptor function by glycine transport

1 reference

12 December 2020

Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective

1 reference

12 December 2020

Apoptotic mechanisms in the pathophysiology of schizophrenia

1 reference

12 December 2020

Ventricular enlargement in poor-outcome schizophrenia

1 reference

12 December 2020

A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings

1 reference

12 December 2020

Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?

1 reference

12 December 2020

Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs

1 reference

12 December 2020

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

12 December 2020

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

1 reference

12 December 2020

A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures

1 reference

12 December 2020

Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.

1 reference

12 December 2020

Competitive and non-competitive NMDA antagonists induce similar limbic degeneration

1 reference

12 December 2020

The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential

1 reference

12 December 2020

Ketamine: an update on the first twenty-five years of clinical experience

1 reference

12 December 2020

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach

1 reference

12 December 2020

Treatment of negative and cognitive symptoms

1 reference

12 December 2020

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

12 December 2020

The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

1 reference

12 December 2020

Mice with reduced NMDA receptor expression display behaviors related to schizophrenia

1 reference

12 December 2020

Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction

1 reference

12 December 2020

Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro.

1 reference

12 December 2020

A review of MRI findings in schizophrenia

1 reference

12 December 2020

Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury

1 reference

12 December 2020

Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning

1 reference

12 December 2020

The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis

1 reference

12 December 2020

The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.

1 reference

12 December 2020

Dysregulation of mesoprefrontal dopamine neurons induced by acute and repeated phencyclidine administration in the nonhuman primate: implications for schizophrenia.

1 reference

12 December 2020

M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice

1 reference

12 December 2020

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

12 December 2020

Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test.

1 reference

12 December 2020

A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

1 reference

12 December 2020

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study

1 reference

12 December 2020

Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment

1 reference

12 December 2020

A separate disease within the syndrome of schizophrenia

1 reference

12 December 2020

Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence

1 reference

12 December 2020

1 reference

12 December 2020

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis

1 reference

12 December 2020

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

12 December 2020

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

12 December 2020

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

Glutamate toxicity in chronic neurodegenerative disease.

1 reference

12 December 2020

D-alanine added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

12 December 2020

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

1 reference

12 December 2020

Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.

1 reference

12 December 2020

Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?

1 reference

12 December 2020

D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release

1 reference

12 December 2020

Neuroanatomy and neurophysiology in schizophrenia

1 reference

12 December 2020

Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats

1 reference

12 December 2020

D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia

1 reference

12 December 2020

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

1 reference

12 December 2020

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

Molecular diversity of glutamate receptors and implications for brain function

1 reference

12 December 2020

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

1 reference

12 December 2020

NMDA receptor hypofunction model of schizophrenia

1 reference

12 December 2020

D-cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats.

1 reference

12 December 2020

D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task

1 reference

12 December 2020

Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations.

1 reference

12 December 2020

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

1 reference

12 December 2020

Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults

1 reference

12 December 2020

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

12 December 2020

Role of glycine in the N-methyl-D-aspartate-mediated neuronal cytotoxicity

1 reference

12 December 2020

Oral ketamine preanesthetic medication in children.

1 reference

12 December 2020

Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

12 December 2020

Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs

1 reference

12 December 2020

Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia

1 reference

12 December 2020

d-Cycloserine therapy of psychosis by symptom provocation

1 reference

12 December 2020

13. Early intervention with neuroleptics may decrease the l long-term morbidity of schizophrenia

1 reference

12 December 2020

Glycine potentiates the NMDA response in cultured mouse brain neurons

1 reference

12 December 2020

Glycine therapy of schizophrenia

1 reference

12 December 2020

D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics

1 reference

12 December 2020

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

1 reference

12 December 2020

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

1 reference

12 December 2020

d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

12 December 2020

Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes

1 reference

12 December 2020

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia

1 reference

12 December 2020

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

1 reference

12 December 2020

Glutamate receptor function in learning and memory

1 reference

12 December 2020

Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys

1 reference

12 December 2020

An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy.

1 reference

12 December 2020

10.1007/S00406-007-0757-8

Identifiers

DOI

1 reference

release_gqaa6rn665be3oegj4apizhdmy

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gqaa6rn665be3oegj4apizhdmy

24 November 2022

mapped directly with Wikidata item

1 reference